High risk of cancer in autoimmune necrotizing myopathies: Usefulness of myositis specific antibody

Brain

Volumn 139, Issue 8, 2016, Pages 2131-2135

  Allenbach, Yves ^a,b   Keraen, Jeremy ^a   Bouvier, Anne Marie ^c   Jooste, Valérie ^c   Champtiaux, Nicolas ^a   Hervier, Baptiste ^a   Schoindre, Yoland ^a   Rigolet, Aude ^a   Gilardin, Laurent ^a   Musset, Lucile ^d   Charuel, Jean Luc ^d   Boyer, Olivier ^e   Jouen, Fabienne ^e   Drouot, Laurent ^e   Martinet, Jeremie ^e   Stojkovic, Tanya ^d   Eymard, Bruno ^d   Laforêt, Pascal ^d   Behin, Antony ^d   Salort Campana, Emmanuelle ^f   Fain, Olivier ^g   Meyer, Alain ^h   Schleinitz, Nicolas ^f   Mariampillai, Kuberaka ^a,b   Grados, Aurelie ^a   Benveniste, Olivier ^a,b   more..

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Sorbonne Université   (France)

^c DIJON UNIVERSITY HOSPITAL   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e ROUEN UNIVERSITY HOSPITAL   (France)

^f TIMONE HOSPITAL   (France)

^g ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^h HÔPITAL CIVIL   (France)

Author keywords

auto antibodies; cancer; necrotizing autoimmune myopathies; polymyositis

Indexed keywords

AUTOANTIBODY; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE ANTIBODY; MYOSITIS SPECIFIC ANTIBODY; SIGNAL RECOGNITION PARTICLE ANTIBODY; UNCLASSIFIED DRUG; HMGCR PROTEIN, HUMAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE NECROTIZING MYOPATHY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDIAN SURVIVAL TIME; MIDDLE AGED; MYOSITIS; POPULATION; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME; VERY ELDERLY; AUTOIMMUNE DISEASES; BLOOD; CLINICAL TRIAL; COMORBIDITY; DERMATOMYOSITIS; IMMUNOLOGY; MULTICENTER STUDY; MUSCULAR DISEASES; NEOPLASMS;

ADULT; AGED; AUTOANTIBODIES; AUTOIMMUNE DISEASES; COMORBIDITY; DERMATOMYOSITIS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; MALE; MIDDLE AGED; MUSCULAR DISEASES; MYOSITIS; NEOPLASMS;

EID: 84982915259     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aww054     Document Type: Article

References (17)

1. Allenbach Y, Benveniste O. Acquired necrotizing myopathies. Curr Opin Neurol 2013; 26: 554-60.
2. Allenbach Y, Drouot L, Rigolet A, Charuel JL, Jouen F, Romero NB, et al. Anti-HMGCR autoantibodies in european patients with autoimmune necrotizing myopathies: inconstant exposure to statin. Medicine (Baltimore) 2014; 93: 150-7.
3. Antiochos BB, Brown LA, Li Z, Tosteson TD, Wortmann RL, Rigby WFC. Malignancy is associated with dermatomyositis but not polymyositis in Northern New England, USA. J Rheumatol 2009; 36: 2704-10.
4. Drouot L, Allenbach Y, Jouen F, Charuel J-L, Martinet J, Meyer A, et al. Exploring necrotizing autoimmune myopathies with a novel immunoassay for anti-3-hydroxy-3-methyl-glutaryl-CoA reductase autoantibodies. Arthritis Res Ther 2014; 16: R39.
5. Fiorentino DF, Chung LS, Christopher-Stine L, Zaba L, Li S, Mammen AL, et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1g. Arthritis Rheum 2013; 65: 2954-62.
6. Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet Lond Engl 2001; 357: 96-100.
7. Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 2004; 14: 337-45.
8. Joseph CG, Darrah E, Shah AA, Skora AD, Casciola-Rosen LA, Wigley FM, et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 2014; 343: 152-7.
9. Levin MI, Mozaffar T, Al-Lozi MT, Pestronk A. Paraneoplastic necrotizing myopathy: clinical and pathological features. Neurology 1998; 50: 764-7.
10. Limaye V, Bundell C, Hollingsworth P, Rojana-Udomsart A, Mastaglia F, Blumbergs P, et al. Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase in patients with immune-mediated myositis and necrotizing myopathy. Muscle Nerve 2015; 52: 196-203.
11. Mammen AL, Chung T, Christopher-Stine L, Rosen P, Rosen A, Doering KR, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 2011; 63: 713-21.
12. Miller T, Al-Lozi MT, Lopate G, Pestronk A. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 2002; 73: 420-8.
13. Torres C, Belmonte R, Carmona L, Gómez-Reino FJ, Galindo M, Ramos B, et al. Survival, mortality and causes of death in inflammatory myopathies. Autoimmunity 2006; 39: 205-15.
14. Trallero-Araguás E, Rodrigo-Pendás JA, Selva-O'Callaghan A, Martńez-Gómez X, Bosch X, Labrador-Horrillo M, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum 2012; 64: 523-32.
15. Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senecal JL. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medecine (Baltimore) 2005; 84: 231-49.
16. Vu HJ, Pham D, Makary R, Nguyen T, Shuja S. Paraneoplastic necrotizing myopathy presenting as severe muscle weakness in a patient with small-cell lung cancer: successful response to chemoradiation therapy. Clin Adv Hematol Oncol 2011; 9: 557-556.
17. Zahr ZA, Baer AN. Malignancy in myositis. Curr Rheumatol Rep 2011; 13: 208-15.